STING1 gain-of-function mutations enhanced type I IFN pathway activation and treatment of lymphocytes from SAVI patients with JAK1/2 inhibitors reduced the constitutive phosphorylation of STAT1 [9], thereby defining SAVI as a novel type I interferonopathy. The gene discussed is JAK1; the disease is STING-associated vasculopathy with onset in infancy.